We believe that ABCB1 genotyping has a great potential to be incorporated into CPIC guidelines and clinical practice and that could enable early identification of patients at risk of development of SAMS, which would lead to improved statin therapy and better clinical management of patients. This evidence concerns the gene ABCB1 and short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.